Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 1
2006 1
2007 1
2008 3
2009 3
2010 1
2011 1
2012 7
2013 5
2014 3
2015 7
2016 3
2017 4
2018 6
2019 11
2020 8
2021 11
2022 13
2023 9
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

91 results

Results by year

Filters applied: . Clear all
Page 1
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma.
Zhu AX, Abbas AR, de Galarreta MR, Guan Y, Lu S, Koeppen H, Zhang W, Hsu CH, He AR, Ryoo BY, Yau T, Kaseb AO, Burgoyne AM, Dayyani F, Spahn J, Verret W, Finn RS, Toh HC, Lujambio A, Wang Y. Zhu AX, et al. Among authors: he ar. Nat Med. 2022 Aug;28(8):1599-1611. doi: 10.1038/s41591-022-01868-2. Epub 2022 Jun 23. Nat Med. 2022. PMID: 35739268
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial.
Yau T, Zagonel V, Santoro A, Acosta-Rivera M, Choo SP, Matilla A, He AR, Cubillo Gracian A, El-Khoueiry AB, Sangro B, Eldawy TE, Bruix J, Frassineti GL, Vaccaro GM, Tschaika M, Scheffold C, Koopmans P, Neely J, Piscaglia F. Yau T, et al. Among authors: he ar. J Clin Oncol. 2023 Mar 20;41(9):1747-1757. doi: 10.1200/JCO.22.00972. Epub 2022 Dec 13. J Clin Oncol. 2023. PMID: 36512738 Free PMC article. Clinical Trial.
Pathogenesis to management of hepatocellular carcinoma.
Da BL, Suchman KI, Lau L, Rabiee A, He AR, Shetty K, Yu H, Wong LL, Amdur RL, Crawford JM, Fox SS, Grimaldi GM, Shah PK, Weinstein J, Bernstein D, Satapathy SK, Chambwe N, Xiang X, Mishra L. Da BL, et al. Among authors: he ar. Genes Cancer. 2022 Dec 13;13:72-87. doi: 10.18632/genesandcancer.226. eCollection 2022. Genes Cancer. 2022. PMID: 36533190 Free PMC article. Review.
The Role of Angiogenesis in Hepatocellular Carcinoma.
Morse MA, Sun W, Kim R, He AR, Abada PB, Mynderse M, Finn RS. Morse MA, et al. Among authors: he ar. Clin Cancer Res. 2019 Feb 1;25(3):912-920. doi: 10.1158/1078-0432.CCR-18-1254. Epub 2018 Oct 1. Clin Cancer Res. 2019. PMID: 30274981 Review.
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer.
Oh DY, He AR, Qin S, Chen LT, Okusaka T, Vogel A, Kim JW, Suksombooncharoen T, Lee MA, Kitano M, Burris H, Bouattour M, Tanasanvimon S, McNamara MG, Zaucha R, Avallone A, Tan B, Cundom J, Lee CK, Takahashi H, Ikeda M, Chen JS, Wang J, Makowsky M, Rokutanda N, Żotkiewicz M, Kurland JF, Cohen G, Valle JW. Oh DY, et al. Among authors: he ar. Future Oncol. 2023 Nov;19(34):2277-2289. doi: 10.2217/fon-2023-0468. Epub 2023 Sep 25. Future Oncol. 2023. PMID: 37746835 Free article. Review.
Systemic Treatment for Advanced Hepatocellular Carcinoma.
Bouattour M, Mehta N, He AR, Cohen EI, Nault JC. Bouattour M, et al. Among authors: he ar. Liver Cancer. 2019 Oct;8(5):341-358. doi: 10.1159/000496439. Epub 2019 Mar 6. Liver Cancer. 2019. PMID: 31768344 Free PMC article. Review.
91 results